MXCT - MaxCyte GAAP EPS of -$0.11 revenue of $8.6M
2023-05-10 16:29:01 ET
- MaxCyte press release ( NASDAQ: MXCT ): Q1 GAAP EPS of -$0.11.
- Revenue of $8.6M (-25.7% Y/Y).
- Total cash, cash equivalents and short-term investments were $224.7 million as of March 31, 2023.
-
Gross profit for the first quarter of 2023 was $7.6 million (88% gross margin), compared to $10.5 million (91% gross margin) in the first quarter of 2022.
-
Operating expenses for the first quarter of 2023 were $20.8 million, compared to operating expenses of $14.7 million in the first quarter of 2022.
For further details see:
MaxCyte GAAP EPS of -$0.11, revenue of $8.6M